ACR 2016

Sustained Disease Control Seen With Long-Term Belimumab in SLE

By November 16, 2016

Long-term safety and efficacy data from a continuation study of Benlysta in patients with systemic lupus erythematosus (SLE) has been released.

Smoking Leads to Worse RA Flare and Remission Patterns

By November 16, 2016

Tobacco smoking adversely impacts rheumatoid arthritis (RA) flare and remission rates, according to findings from a long-term retrospective, population-based cohort study, presented at the 2016 ACR/ARHP Annual Meeting.

Temporary MTX Discontinuation Ups Flu Vaccine Efficacy in RA

By November 16, 2016

Temporarily discontinuing methotrexate (MTX) treatment can improve seasonal influenza vaccination immunogenicity among patients with rheumatoid arthritis (RA), according to a single center, randomized, single-blind, open-label prospective study (NCT02748785) presented at the 2016 ACR/ARHP Annual Meeting.

Infliximab vs. Biosimilar: Discontinuation Rates Compared

By November 16, 2016

Medical records of 1,044 patients with RA, new to starting treatment with Remicade or CT-P13, were analyzed in the study.

Anti-TNF Agents Go Head-to-Head in RA Superiority Study

By November 16, 2016

The trial compares short- and long-term outcomes of Cimzia and Humira in RA

Tofacitinib Effective in PsA Patients With Prior Inadequate Response

By November 16, 2016

Statistically significant improvements were shown 3 months vs. placebo with tofacitinib, in this new study

Large RA Survey Finds 61% of Patients Uncomfortable Voicing Concerns

By November 16, 2016

Results from a global survey given to patients and physicians showed that good communication is "critical to achieve optimal care".

Sarilumab Offers Durable Clinical Responses for RA After 3 Years

By November 16, 2016

The IL-6Rα -targeting human mAb sarilumab offers durable responses against rheumatoid arthritis (RA), according to an analysis of 3-year clinical and radiographic outcomes and safety for patients from the MOBILITY open-label extension study.

Sarilumab Efficacy, Safety Comparable Among RA Patient Subgroups

By November 16, 2016

The IL-6Rα -targeting human mAb sarilumab exhibits comparable efficacy and safety for different patient subgroups in rheumatoid arthritis.

Long-Term Adalimumab Reduces Uveitis and Corticosteroid Dose

By November 16, 2016

Adalimumab (Humira) helps treat non-infectious intermediate, posterior, or panuveitis (NIPPU), according to findings from an open-label clinical trial extension, VISUAL-III

Secukinumab Efficacy Assessed in Psoriatic Arthritis

November 15, 2016

Researchers noted a comparable response rate to ACR 20, ACR 50, ACR 90, and PASI 75 in their analyses.

Allopurinol Examined For Possible Protective Effect Against Stroke

November 15, 2016

Allopurinol use was found to be associated with a reduced risk of ischemic stroke.

Novel Biologic Guselkumab Promising in Psoriatic Arthritis Study

By November 15, 2016

Subcutaneous guselkumab treatment tested in patients with psoriatic arthritis

Rituximab Compared to TNFi for First-Line Therapy in RA with Interstitial Lung Disease

November 15, 2016

For RA patients with interstitial lung disease, rituximab linked to improved survival versus TNFi

Tocilizumab Superior to Steroids Alone for Giant Cell Arteritis Remission

By November 15, 2016

Positive data was presented for Actemra (tocilizumab) therapy in patients with giant cell arteritis (GCA).

Biosimilars for Rheumatic Diseases: Safety, Efficacy of Switching Assessed

By November 15, 2016

The investigators found switching data for 12 studies in rheumatic diseases.

Demand for Rheumatologists Exceeds Supply

November 15, 2016

By 2030, excess demand expected to be 138 percent more than supply, versus 36 percent currently

Hidradenitis Suppurativa Responsive to TNF Inhibitor Therapy

By November 15, 2016

Tumor necrosis factor (TNF) inhibitors yield promising responses among patients with chronic, recurring-abscessing sweat-gland inflammation known as hidradenitis suppurativa (HS).

How Do DMARDs Alter Diabetes Risk in Rheumatoid Arthritis?

November 15, 2016

Hydroxychloroquine use was associated with a duration-dependent reduction in risk of developing diabetes.

Clinical Profile for Diagnostic Delay in Psoriatic Arthritis Points to Females, Enthesitis

By November 14, 2016

Several recent studies have shown that a delay in diagnosis of PsA leads to a worse outcome.

Apremilast Demonstrates Early Onset of Efficacy in Active Psoriatic Arthritis

By November 14, 2016

The objective was to determine the clinical effects of Otezla vs. placebo through its early efficacy outcomes

Allopurinol Skin Reactions in Gout Might Predict Febuxostat Reactions

By November 14, 2016

Use of febuxostat (FBX) might cause skin reactions in some patients with gout who have experienced such reactions after allopurinol administration.

Uveitis in Ankylosing Spondylitis: Risk Factors Identified

By November 14, 2016

Uveitis should be suspected in patients with ankylosing spondylitis (AS) who have high lesion counts, antistreptolysin O (ASO) and circulating immune complex (CIC) titers

Golimumab Improves Symptoms in Patients with Ankylosing Spondylitis

By November 14, 2016

The study's primary endpoint was an improvement in Assessment in Ankylosing Spondylitis of at least 20%

Ixekizumab Evaluated in Patients with Psoriatic Arthritis

November 13, 2016

Treatment of psoriatic arthritis (PsA) with ixekizumab (IXE)—an IgG4 monoclonal antibody—significantly improves arthritis, dactylitis and enthesitis at 52-weeks

Adding Adalimumab to Methotrexate in RA Halts Radiographic Progression

By November 13, 2016

In patients with early RA, conventional synthetic DMARDs are recommended as first-line therapy

Consider Cycling to Different TNFi Before Swapping in RA Patients with Inadequate TNFi Response

By November 13, 2016

Cycling to a different tumor necrosis factor alpha inhibitor (TNFi) after treatment failure in patients with rheumatoid arthritis (RA) can be effective.

Weekly Adalimumab Safe, Effective in Children with JIA and Chronic Uveitis

By November 13, 2016

Weekly adalimumab was used most commonly to treat uveitis

Polyarticular JIA-associated Uveitis Well-Controlled with Adalimumab ± Methotrexate

By November 13, 2016

Juvenile idiopathic arthritis (JIA)-associated uveitis was well-controlled with adalimumab and/or methotrexate.

In Knee OA, Only One Treatment Effective for Long-Term Control of Symptoms, Joint Changes

By November 13, 2016

Glucosamine sulfate is the only agent consistently effective on symptoms and joint structure changes in patients with knee osteoarthritis (OA).